Alcohol

More documents

Recommendations

Info

Receptor Blockade with Naltrexone in <strong>Alcohol</strong>ics (50mg) 93% blockade of µ receptors, 24 hours, all SS C 11 carfentanil Variable (22.8 +/- 12%) blockade of ∂ receptors C 11 N methyl naltrindole, 24 hrs. * McCaul et al 2004
Double blind design • 70 chronic alcoholics • All received intensive day hospital, AA, psychotherapy • Half received Naltrexone 50 mg/day • Half received identical placebo • Weekly craving scores • “slips” measured (not a relapse) • Relapse defined
Page 1 and 2: The Path to Genomic Medicine For Ad
Page 3 and 4: Use Use Use Use Use Abuse (declarat
Page 5 and 6: Possible Changes • Addiction inst
Page 7 and 8: Addiction: Loss of control • Jean
Page 9 and 10: Possible Families of Risk Factors
Page 11 and 12: Response • Genetically influenced
Page 13 and 14: Drugs of Abuse all Activate Reward
Page 15 and 16: Effects of Drugs on Dopamine Levels
Page 17 and 18: Relationship between Cue-Induced De
Page 19: “Unseen” Reward Cues activate a
Page 22 and 23: Alcoholism: FDA Approved Medication
Page 24 and 25: Alcohol - Beverage Condition Cingul
Page 26 and 27: Baclofen blunts Amygdala Connectivi
Page 28 and 29: Alcohol reward Sedating drug, facil
Page 30 and 31: True Translational Story: Naltrexon
Page 32: Naltrexone decreases Alcohol prefer
Page 38 and 39: Ethanol Responses Saline 80 70 60 5
Page 40 and 41: Naltrexone Concurrently Antagonizes
Page 42 and 43: Brain Reward System Nucleus Accumbe
Page 44 and 45: Dopamine Opioid Antagonism Dopamine
Page 46 and 47: Propose an RCT of an opiate antagon
Page 48 and 49: Naltrexone Affinity at Opioid Recep
Page 52 and 53: Post-Docs Tom Aronson, MD Joseph Vo
Page 54 and 55: Pharmacological Treatments for Alco
Page 56 and 57: Days Drinking 1.0 0.8 0.6 0.4 0.2 0
Page 58 and 59: Alcohol Relapse A. coming to treatm
Page 60 and 61: Rates of Never Relapsing According
Page 62 and 63: Blood Alcohol levels (g/dl) 0.1 0.0
Page 64 and 65: Studies supporting efficacy Studies
Page 66 and 67: Baseline Craving Scores % Days Heav
Page 68 and 69: Baseline b-Endorphin Levels in Low-
Page 70 and 71: Key effect: Sensitivity of Endogeno
Page 72 and 73: BAES Stimulation Scores Among FH+ a
Page 74 and 75: Human Mu Opioid Receptor Gene PROMO
Page 76 and 77: Alcohol effects by genotype 50 45 4
Page 78 and 79: Lotsch et al, 2006
Page 80 and 81: Ethnicity & A118G Allele Frequency
Page 82 and 83: Subjective “high” in Naltrexone
Page 84 and 85: OPRM1 A118G and Alcoholism Bart et
Page 86 and 87: COMBINE Study • N = 1383; 9 rando
Page 88 and 89: Rhesus model Ortholog of A118G alle
Page 90 and 91: Results: Heavy Drinking Days 30 75
Page 92 and 93: Endophenotype Endorphin Dependent A
Page 94 and 95: Medications • Nicotine Nicotine p
Page 96 and 97: FOR MORE INFORMATION http://www.med

Alcohol

Create successful ePaper yourself

Delete template?

Save as template?